DRUG revenueFY2025C$1.52M
- FY YoY
- 50x
DRUG revenue was C$1.52M for fiscal 2025 (ended Sep 30, 2025), up about 50-fold from fiscal 2024.
Bright Minds Biosciences Inc. (DRUG) financials
For fiscal 2025 (ended Sep 30, 2025), Bright Minds Biosciences Inc. reported C$1.52M of revenue and -C$12.23M of net income. Figures are in CAD, the currency of its SEC filings.
- Revenue, FY2025
- C$1.52M
- Revenue growth, YoY
- +4942.5%
- Net income, FY2025
- -C$12.23M
- Net margin
- -804.8%
- Cash
- C$82.91M
FY2022FY2025
FY2020FY2025
DRUG revenue and earnings growth
DRUG net incomeFY2025-C$12.23M
DRUG net income was -C$12.23M for fiscal 2025 (ended Sep 30, 2025), compared with -C$2.80M in fiscal 2024.
DRUG EPSFY2024-C$0.65
DRUG diluted EPS was -C$0.65 for fiscal 2024 (ended Sep 30, 2024), compared with -C$1.98 in fiscal 2023.
Income statement
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 |
|---|---|---|---|---|---|---|
| Revenue | C$1.52M | C$30.1K | C$0 | C$0 | - | - |
| Research and development | C$11.08M | C$1.18M | C$5.00M | C$12.18M | C$6.31M | C$354.9K |
| Selling, general and admin | C$784.1K | C$264.0K | C$278.8K | C$478.2K | C$197.1K | C$637 |
| Income tax | C$0 | C$0 | C$0 | C$0 | C$0 | C$0 |
| Net income | -C$12.23M | -C$2.80M | -C$7.37M | -C$14.96M | -C$8.65M | -C$480.4K |
| EPS, basic | -C$1.78 | -C$0.65 | -C$1.98 | -C$6.06 | -C$4.82 | - |
| EPS, diluted | - | -C$0.65 | -C$1.98 | -C$6.06 | -C$4.82 | -C$0.65 |
| Diluted shares | 6.9M | 4.3M | 3.7M | 2.5M | 1.8M | 722,487.2 |
Balance sheet
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | C$82.91M | C$5.72M | C$6.75M | C$11.63M | C$19.76M | C$799.9K |
| Current assets | C$84.31M | C$5.99M | C$6.81M | C$11.95M | C$20.04M | C$878.2K |
| Total assets | C$84.42M | C$6.10M | C$6.88M | C$12.09M | C$20.04M | C$880.2K |
| Current liabilities | C$2.34M | C$528.7K | C$280.9K | C$1.47M | C$638.6K | - |
| Total liabilities | C$2.38M | C$568.3K | C$280.9K | C$1.54M | C$638.6K | C$150.9K |
| Shareholders' equity | C$82.04M | C$5.54M | C$6.60M | C$10.54M | C$19.40M | C$729.3K |
Cash flow
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -C$8.69M | -C$1.85M | -C$7.02M | -C$13.59M | -C$7.32M | -C$288.4K |
| Financing cash flow | C$85.57M | C$810.6K | C$2.19M | C$5.20M | C$26.06M | C$1.01M |
| Stock-based compensation | C$3.18M | C$839.8K | C$1.15M | C$875.1K | C$880.6K | C$161.3K |
| Depreciation and amortization | C$76.9K | C$73.4K | C$72.5K | C$6.0K | C$0 | C$0 |
Key ratios
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 |
|---|---|---|---|---|---|---|
| Revenue growth, YoY | 4942.5% | - | - | - | - | - |
| Net margin | -804.8% | -9298.6% | - | - | - | - |
| Return on equity | -14.9% | -50.6% | -111.7% | -141.9% | -44.6% | -65.9% |
| Return on assets | -14.5% | -45.9% | -107.2% | -123.8% | -43.2% | -54.6% |
| Current ratio | 36.10 | 11.32 | 24.26 | 8.11 | 31.38 | - |
Source: XBRL data Bright Minds Biosciences Inc. files with the SEC, latest filing dated Dec 23, 2025 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-5, first reported Dec 29, 2023.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
DRUG peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| DRUG | C$1.52M | +4942.5% | -C$12.23M | -804.8% | $236.7M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
DRUG FAQ
6 questionsWhat is DRUG revenue?
Bright Minds Biosciences Inc. (DRUG) reported C$1.52M of revenue for fiscal 2025 (ended Sep 30, 2025). That is up 4942.5% from the year before.Is DRUG profitable?
No. Bright Minds Biosciences Inc. reported a net loss of C$12.23M for fiscal 2025 (ended Sep 30, 2025).How much cash and debt does DRUG have?
Bright Minds Biosciences Inc. reported C$82.91M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is DRUG revenue growing?
Bright Minds Biosciences Inc.'s revenue changed 50x in fiscal 2025, to C$1.52M.When did DRUG last report financial results?
The latest statements here come from Bright Minds Biosciences Inc.'s 40-F filed on Dec 23, 2025, covering the period ended Sep 30, 2025.Where does this DRUG financial data come from?
Quantisnow builds these statements from the structured XBRL data Bright Minds Biosciences Inc. files with the SEC. It is provided for information only and is not investment advice.